AI Article Synopsis
- The treatment for atopic dermatitis has remained largely the same for years, but new biologic therapies are being developed due to better understanding of the disease's immunologic pathways.
- This study reviews the safety and efficacy of monoclonal antibodies from recent clinical trials for treating atopic dermatitis.
- Findings indicate that biologics like dupilumab, lebrikizumab, and nemolizumab are effective and generally safe, highlighting their potential for helping patients with treatment-resistant forms of the condition.
Article Abstract
Background: The mainstay of atopic dermatitis treatment has been largely unchanged over the last few decades. With improved understanding of the immunologic pathways underlying atopic dermatitis in recent years, targeted biologic therapies are being developed.
Objective: Discuss efficacy and safety profiles of emerging biologics in phase 2 and 3 clinical trials.
Methods: A systemic literature review was conducted to identify results of randomized, placebo-controlled trials of monoclonal antibodies up to March 1, 2020 for the treatment of atopic dermatitis.
Results: Targeted biologics appear to have acceptable safety profiles. Dupilumab, lebrikizumab, and nemolizumab demonstrate efficacy as agents producing improvement in clinical severity and pruritus.
Conclusions: The growing class of biologics shows promise in meeting the needs of treatment-resistant atopic dermatitis. The use of validated core measurements is necessary for future trials in order to adequately compare agents and progress evidence-based medicine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2020.1836314 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb)
January 2025
Hospital Universitari Germans Trias I Pujol, UAB, IGTP, Badalona, Spain.
Eczema Herpeticum: A Fatal Rash That Mimics Many.
S D Med
September 2024
Avera Medical Group Infectious Disease Specialists, Sioux Falls, South Dakota.
Eczema herpeticum (EH) is a potentially life-threatening condition, especially in the pediatric population, that occurs among patients with atopic dermatitis (AD). AD is a chronic inflammatory skin disorder with a complex pathophysiology that predisposes patients to EH. Herpes simplex virus (HSV) 1 is implicated in 90 % of EH cases and often initially presents with gingivostomatitis.
View Article and Find Full Text PDFBiomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.
Am J Clin Dermatol
January 2025
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response of AD are traditionally reported through clinical assessments including the Eczema Area and Severity Index or Investigator's Global Assessment. These clinical rating scales are visual assessments used in clinical trials to denotate AD severity.
View Article and Find Full Text PDFAP2M1 as the potential biomarker for prediction of the response of atopic dermatitis to Dupilumab therapy: Multi-omics analysis and evidence.
Int J Biol Macromol
January 2025
Department of Dermatology, the Affiliated Hospital of Guilin Medical University, Guilin Medical University, Guilin, China. Electronic address:
Many atopic dermatitis (AD) patients have suboptimal responses to Dupilumab therapy. This study identified key genes linked to this resistance using multi-omics approaches to benefit more patients. We selected a prospective cohort of 54 CE treated with Dupilumab from the GEO database.
View Article and Find Full Text PDFd-Limonene inhibits cytokines and chemokines expression by regulating NF-kappaB and STAT in HaCat cells and DNCB-induced atopic dermatitis in BALB/c mice.
Int Immunopharmacol
January 2025
School of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan; PhD Program in Pharmaceutical Biotechnology, Fu Jen Catholic University, New Taipei City 24205, Taiwan; School of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. Electronic address:
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by itching and redness, affecting individuals of all ages and significantly impairing their quality of life. The prevalence of AD is rising, posing serious health concern. Relief of itching is a primary treatment objective; however, steroid treatments can lead to adverse effects, including skin barrier thinning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!